KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2025)

Acadia Pharmaceuticals has reported Raw Materials over the past 10 years, most recently at $82.8 million for Q4 2025.

  • Quarterly results put Raw Materials at $82.8 million for Q4 2025, up 18.7% from a year ago — trailing twelve months through Dec 2025 was $82.8 million (up 18.7% YoY), and the annual figure for FY2025 was $82.8 million, up 18.7%.
  • Raw Materials for Q4 2025 was $82.8 million at Acadia Pharmaceuticals, up from $77.8 million in the prior quarter.
  • Over the last five years, Raw Materials for ACAD hit a ceiling of $83.7 million in Q2 2025 and a floor of $1.5 million in Q2 2021.
  • Median Raw Materials over the past 5 years was $11.5 million (2023), compared with a mean of $32.4 million.
  • Biggest five-year swings in Raw Materials: plummeted 43.83% in 2021 and later surged 934.36% in 2024.
  • Acadia Pharmaceuticals' Raw Materials stood at $6.2 million in 2021, then decreased by 16.25% to $5.2 million in 2022, then surged by 501.34% to $31.3 million in 2023, then soared by 122.73% to $69.7 million in 2024, then grew by 18.7% to $82.8 million in 2025.
  • The last three reported values for Raw Materials were $82.8 million (Q4 2025), $77.8 million (Q3 2025), and $83.7 million (Q2 2025) per Business Quant data.